Kalaris Therapeutics Inc. (NASDAQ:KLRS) Short Interest Update

Kalaris Therapeutics Inc. (NASDAQ:KLRS) saw a significant decrease in short interest in the month of April. As of April 15th, there was short interest totaling 842,687 shares, a decrease of 15.3% from the March 31st total of 995,274 shares. Currently, 14.7% of the company’s shares are short sold. Based on an average trading volume of 88,874 shares, the short-interest ratio is presently 9.5 days.

Kalaris Therapeutics Trading Down 0.8%

Kalaris Therapeutics stock traded down $0.04 during mid-day trading on Friday, hitting $5.48. The company’s stock had a trading volume of 80,551 shares, compared to its average volume of 73,063. The stock’s fifty day moving average is $7.44 and its two-hundred day moving average is $7.47. Kalaris Therapeutics has a 1 year low of $2.14 and a 1 year high of $11.88. The firm has a market capitalization of $125.94 million, a PE ratio of -1.30 and a beta of 0.18.

Kalaris Therapeutics (NASDAQ:KLRS) last released its quarterly earnings results on Tuesday, March 17th. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.12. On average, equities analysts expect that Kalaris Therapeutics will post -2.18 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on KLRS shares. Wall Street Zen upgraded Kalaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. Morgan Stanley started coverage on Kalaris Therapeutics in a research report on Thursday, April 16th. They issued an “overweight” rating and a $14.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $14.00.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in KLRS. RTW Investments LP acquired a new position in Kalaris Therapeutics during the fourth quarter worth $10,972,000. Paradigm Biocapital Advisors LP acquired a new position in Kalaris Therapeutics during the fourth quarter worth $5,908,000. Alyeska Investment Group L.P. acquired a new position in Kalaris Therapeutics during the fourth quarter worth $3,402,000. Ikarian Capital LLC acquired a new position in Kalaris Therapeutics during the fourth quarter worth $3,038,000. Finally, Woodline Partners LP acquired a new position in Kalaris Therapeutics during the third quarter worth $1,394,000. 66.05% of the stock is currently owned by institutional investors and hedge funds.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.